A citation-based method for searching scientific literature

Titia G Meijer, Luan Nguyen, Arne Van Hoeck, Anieta M Sieuwerts, Nicole S Verkaik, Marjolijn M Ladan, Kirsten Ruigrok-Ritstier, Carolien H M van Deurzen, Harmen J G van de Werken, Esther H Lips, Sabine C Linn, Yasin Memari, Helen Davies, Serena Nik-Zainal, Roland Kanaar, John W M Martens, Edwin Cuppen, Agnes Jager, Dik C van Gent. Oncogene 2022
Times Cited: 2







List of co-cited articles
16 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
77
100

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Tamara L Lotan, Harsimar B Kaur, Daniela C Salles, Sanjana Murali, Edward M Schaeffer, Jerry S Lanchbury, William B Isaacs, Robert Brown, Andrea L Richardson, Olivier Cussenot,[...]. Mod Pathol 2021
29
100

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
Ádám Póti, Hella Gyergyák, Eszter Németh, Orsolya Rusz, Szilárd Tóth, Csenger Kovácsházi, Dan Chen, Bernadett Szikriszt, Sándor Spisák, Shunichi Takeda,[...]. Genome Biol 2019
51
100

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
321
100

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
133
100

Biomarkers for Homologous Recombination Deficiency in Cancer.
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
161
100

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
735
100

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
412
100

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
297
100

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
375
100

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
493
100

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
737
100

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
913
100

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Melinda L Telli, Kristin C Jensen, Shaveta Vinayak, Allison W Kurian, Jafi A Lipson, Patrick J Flaherty, Kirsten Timms, Victor Abkevich, Elizabeth A Schackmann, Irene L Wapnir,[...]. J Clin Oncol 2015
164
100

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
679
100

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
249
50

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Francis W Hunter, Bradly G Wouters, William R Wilson. Br J Cancer 2016
119
50

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, Aron C Eklund, Zhigang C Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh,[...]. J Clin Oncol 2010
705
50


ATM's Role in the Repair of DNA Double-Strand Breaks.
Atsushi Shibata, Penny A Jeggo. Genes (Basel) 2021
16
50

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley,[...]. Science 2016
50

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
50

Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Harsimar B Kaur, Thiago Vidotto, Adrianna A Mendes, Daniela C Salles, William B Isaacs, Emmanuel S Antonarakis, Tamara L Lotan. Cancer Immunol Immunother 2022
3
50

Mutational signatures: emerging concepts, caveats and clinical applications.
Gene Koh, Andrea Degasperi, Xueqing Zou, Sophie Momen, Serena Nik-Zainal. Nat Rev Cancer 2021
45
50

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M Tung, Mark E Robson, Steffen Ventz, Cesar A Santa-Maria, Rita Nanda, Paul K Marcom, Payal D Shah, Tarah J Ballinger, Eddy S Yang, Shaveta Vinayak,[...]. J Clin Oncol 2020
147
50


Chromothripsis and cancer: causes and consequences of chromosome shattering.
Josep V Forment, Abderrahmane Kaidi, Stephen P Jackson. Nat Rev Cancer 2012
241
50

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
15
50


Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Elizabeth Alli, Vandana B Sharma, Anne-Renee Hartman, Patrick S Lin, Lisa McPherson, James M Ford. BMC Pharmacol 2011
31
50

Ataxia telangiectasia: a review.
Cynthia Rothblum-Oviatt, Jennifer Wright, Maureen A Lefton-Greif, Sharon A McGrath-Morrow, Thomas O Crawford, Howard M Lederman. Orphanet J Rare Dis 2016
265
50

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Virginia G Kaklamani, Jacqueline S Jeruss, Elisha Hughes, Kalliopi Siziopikou, Kirsten M Timms, Alexander Gutin, Victor Abkevich, Zaina Sangale, Cara Solimeno, Krystal L Brown,[...]. Breast Cancer Res Treat 2015
48
50

Whole genomes redefine the mutational landscape of pancreatic cancer.
Nicola Waddell, Marina Pajic, Ann-Marie Patch, David K Chang, Karin S Kassahn, Peter Bailey, Amber L Johns, David Miller, Katia Nones, Kelly Quek,[...]. Nature 2015
50

Signatures of copy number alterations in human cancer.
Christopher D Steele, Ammal Abbasi, S M Ashiqul Islam, Amy L Bowes, Azhar Khandekar, Kerstin Haase, Shadi Hames-Fathi, Dolapo Ajayi, Annelien Verfaillie, Pawan Dhami,[...]. Nature 2022
16
50

Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Adriaan Vanderstichele, Pieter Busschaert, Siel Olbrecht, Diether Lambrechts, Ignace Vergote. Eur J Cancer 2017
35
50

Homologous Recombination Subpathways: A Tangle to Resolve.
Amira Elbakry, Markus Löbrich. Front Genet 2021
13
50

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
Emma Nolan, Peter Savas, Antonia N Policheni, Phillip K Darcy, François Vaillant, Christopher P Mintoff, Sathana Dushyanthen, Mariam Mansour, Jia-Min B Pang, Stephen B Fox,[...]. Sci Transl Med 2017
177
50

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
492
50

Substitution mutational signatures in whole-genome-sequenced cancers in the UK population.
Andrea Degasperi, Xueqing Zou, Tauanne Dias Amarante, Andrea Martinez-Martinez, Gene Ching Chiek Koh, João M L Dias, Laura Heskin, Lucia Chmelova, Giuseppe Rinaldi, Valerie Ya Wen Wang,[...]. Science 2022
17
50

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
Wungki Park, Jiapeng Chen, Joanne F Chou, Anna M Varghese, Kenneth H Yu, Winston Wong, Marinela Capanu, Vinod Balachandran, Caitlin A McIntyre, Imane El Dika,[...]. Clin Cancer Res 2020
82
50

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
907
50



Mutational signature SBS8 predominantly arises due to late replication errors in cancer.
Vinod Kumar Singh, Arnav Rastogi, Xiaoju Hu, Yaqun Wang, Subhajyoti De. Commun Biol 2020
17
50

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, Y H Ibrahim, A Gris-Oliver, S Bonache, B Morancho, A Bruna, O M Rueda,[...]. Ann Oncol 2018
189
50

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Mayu Isono, Endang Nuryadi, Ryota Sekine, Takahiro Oike, Sangeeta Kakoti,[...]. Nat Commun 2017
344
50

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V Tinker, Nelson N H Teng, Maria I Harrell, Michael J Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin,[...]. Cancer Discov 2017
218
50

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
Alexander M A van der Wiel, Victoria Jackson-Patel, Raymon Niemans, Ala Yaromina, Emily Liu, Damiënne Marcus, Alexandra M Mowday, Natasja G Lieuwes, Rianne Biemans, Xiaojing Lin,[...]. Mol Cancer Ther 2021
10
50

Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Doga C Gulhan, Jake June-Koo Lee, Giorgio E M Melloni, Isidro Cortés-Ciriano, Peter J Park. Nat Genet 2019
117
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.